Introduction {#s02}
============

The blood--brain barrier (BBB) is formed by a tightly sealed monolayer of brain endothelial cells, which keeps neurotoxic plasma-derived components, RBCs, leukocytes, and pathogens out of the central nervous system (CNS; [@bib192]). The capillary length in mouse and human brain is 0.6 and 650 km, respectively, which accounts for \>85% of total cerebral blood vessel length, providing the largest endothelial surface area for solute transport exchanges between blood and brain, and vice versa (e.g., ∼120 cm^2^/g of brain; [@bib191]; [@bib128]). Endothelium allows free, rapid diffusion of oxygen and carbon dioxide across the BBB. Specialized endothelial transport systems carry energy metabolites, nutrients, and regulatory molecules across the BBB from blood to brain and metabolic waste products and potentially neurotoxic molecules from brain to blood. This includes solute carrier-mediated transport of carbohydrates (e.g., glucose), amino acids, vitamins, hormones, nucleotides, and monocarboxylic acids (e.g., lactate); receptor-mediated transport (RMT) of peptides and proteins; a major facilitator transporter of essential omega-3 (ω-3) fatty acids; ATP-binding cassette active efflux of xenobiotics and drugs; and multiple ion transporters. The BBB transport systems and cellular junctions have been recently reviewed elsewhere ([@bib186]).

The mean distance between the BBB and neurons is ∼8 µm, allowing rapid diffusion of molecules across the brain interstitial space from capillaries to neurons, and vice versa ([@bib128]). The BBB controls the composition of neuronal internal milieu, which is essential for proper neuronal and synaptic functioning ([@bib186]). The BBB-associated mural cells (pericytes) play a key role in the formation and maintenance of the BBB ([@bib5]; [@bib14]; [@bib35]; [@bib159]). BBB breakdown has been shown in Alzheimer's disease (AD; [@bib192]) and is associated with cerebral blood flow (CBF) reductions and impaired hemodynamic responses ([@bib79], [@bib80]; [@bib90]). Recent imaging and biomarker studies suggest an early BBB breakdown and vascular dysregulation in AD detectable before cognitive decline and/or other brain pathologies ([@bib116]; [@bib114], [@bib115]; [@bib150]; [@bib158]; [@bib82]; [@bib167]; [@bib90]). Neuropathological studies also support early contribution of cerebral vessel disease to AD ([@bib164]; [@bib6]).

Here, we briefly summarize key findings from human studies demonstrating BBB breakdown and dysfunction in AD and examine BBB breakdown in transgenic models frequently used to study pathophysiology of AD. We concentrate on animal models carrying major autosomal-dominant AD (ADAD) mutations in human amyloid-β precursor protein (*APP*) and presenilin 1 (*PSEN1*) genes ([@bib186]), *Tau* gene, and apolipoprotein E (*APOE*) ε4 allele, a major genetic risk factor for sporadic, late-onset AD ([@bib171]; [@bib102]). We also briefly discuss findings in pericyte-deficient models, because pericytes maintain BBB integrity and they degenerate in AD ([@bib159]) and AD models ([@bib131]; [@bib139]). Other models associated with BBB breakdown, such as *PGRN* (progranulin)-deficient mice modeling loss-of-function mutations in the *PGRN* gene linked to frontotemporal dementia ([@bib83]), deficiency in endothelial sphingosine-1-phosphate receptor 1 ([@bib181]), and vascular risk factors such as diabetes and hypertension ([@bib58]; [@bib79]; [@bib118]), have been summarized elsewhere.

We focus on CNS capillaries that maintain the largest surface area of the BBB. Additionally, we examine changes in other vascular segments, including arterioles and small arteries, which when disrupted also contribute to a loss of blood-to-brain vascular integrity. We discuss the role of BBB breakdown and dysfunction in the neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of a neurological disorder. We also suggest future cellular and molecular studies to investigate the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapeutic approaches for BBB repair to control neurodegeneration.

BBB breakdown in AD {#s03}
===================

Recent neuroimaging studies in individuals with mild cognitive impairment (MCI) and early AD have shown BBB breakdown in the hippocampus ([@bib114]) and several gray and white matter regions ([@bib167],[@bib168], [@bib169]), respectively, before brain atrophy or dementia. These neuroimaging studies used advanced dynamic contrast-enhanced magnetic resonance imaging (MRI) to determine BBB permeability to the contrast agent Gadolinium. Increased CNS cerebral microbleeds reflecting loss of cerebrovascular integrity have also been shown by MRI studies in 25% of individuals with MCI and 45--78% of individuals with early AD before dementia ([@bib24]; [@bib69]; [@bib182]; [@bib145]; [@bib133]; [@bib144]).

The BBB breakdown in AD has been confirmed by more than 20 independent postmortem human studies showing brain capillary leakages and perivascular accumulation of blood-derived fibrinogen, thrombin, albumin, immunoglobulin G (IgG) and hemosiderin deposits, pericyte and endothelial degeneration, loss of BBB tight junctions, and RBC extravasation, as recently reviewed ([@bib118]). An early cerebrovascular disorder ([@bib164]; [@bib6]), vascular dysregulation ([@bib82]), ischemic vascular damage from comorbidities and vascular risk factors ([@bib79]; [@bib49]; [@bib118]), and small vessel disease of the brain ([@bib174]; [@bib150]; [@bib61]) may introduce additional vascular components contributing to BBB breakdown in AD.

The identification of peripheral macrophages ([@bib78]) and neutrophils ([@bib184]) in the brain in human AD suggests BBB breakdown to circulating leucocytes and their influx into the brain. A novel matrix metalloproteinase radioactive positron emission tomography (PET) ligand was recently used to visualize leukocyte penetration across the BBB and infiltration into the brain in patients with multiple sclerosis ([@bib56]). Similar studies, however, have not yet been performed in AD patients, and it remains unclear whether leukocyte infiltration is a cause or a consequence of BBB breakdown.

Multiple studies with \[^18^F\]Fluoro-2-deoxy-[d]{.smallcaps}-glucose (FDG-PET) in individuals with MCI and early AD showed impaired regional brain uptake of glucose before brain atrophy, neurodegeneration, or conversion to AD, suggesting reduced glucose brain utilization caused by diminished glucose transport across the BBB via endothelial-specific glucose transporter 1 (GLUT1), as recently reviewed ([@bib118]). 2-Deoxy-[d]{.smallcaps}-glucose (2DG) was originally developed by Sokoloff as a surrogate molecule to study brain glucose uptake and utilization ([@bib151]). Similar to glucose, 2DG is transported across the BBB by GLUT1, and after crossing the BBB, it is taken up by different cell types in the brain, including neurons and astrocytes ([@bib34]). 2DG is rapidly phosphorylated by intracellular hexokinase ([@bib152]) and converted in the brain into 2DG-6-phosphate (2DG-6P; [@bib151]; [@bib108]). However, unlike glucose-6-phosphate, which is metabolized further in the glycolytic pathway, 2DG-6P is not a substrate for glucose-6-phosphate isomerase and therefore cannot be converted into fructose-6-phosphate, a necessary step to enter the glycolytic pathway or Krebs cycle, as shown by multiple independent studies ([@bib152]; [@bib151]; [@bib108]; [@bib138]). For example, studies in the mouse brain using enzymatic assays indicated that 1 h after 2DG systemic administration, ∼90% is converted into 2DG-6P and 10% remains as 2DG, with no other significant metabolites found ([@bib108]). This has been confirmed by another study in the mouse brain using thin-layer chromatography and digital autoradiography, which indicated that after 1 h of \[^18^F\]-DG administration, 97% of the \[^18^F\]-DG is converted into \[^18^F\]-DG-6P ([@bib138]). Similarly, at longer time points, such as 90 min after \[^19^F\]-DG administration to rats, 90% of the \[^19^F\]-DG in the brain is converted into \[^19^F\]-DG-6P and/or its epimers that are not metabolized further, whereas 10% remains as \[^19^F\]-DG ([@bib154]). Because of minimal glucose-6-phosphatase activity in the brain ([@bib70]; [@bib151]) and low 2DG-6P membrane permeability, 2DG-6P remains trapped in brain cells ([@bib76]; [@bib154]) and is eliminated very slowly from the brain.

P-glycoprotein (Pgp) dysfunction in BBB active efflux transport of xenobiotics and drugs in individuals with early AD has also been shown using verapamil (Pgp ligand)-PET ([@bib166]; [@bib42]). Implications of BBB breakdown and dysfunction in BBB transport systems for development of brain pathology based on findings in AD models are discussed next.

BBB breakdown in *APP* transgenic models {#s04}
========================================

Transgenic models expressing mutations in human *APP* gene linked to early ADAD have been frequently used to study the pathophysiology of AD and/or develop treatments to control AD-related cerebral β-amyloidosis. Here, we examine BBB breakdown in *APP* transgenic models and its relationship with Alzheimer's amyloid-β (Aβ) pathology, neurodegeneration, and behavioral deficits ([Table 1](#tbl1){ref-type="table"}).

###### BBB breakdown in *APP*, *PSEN1*, *Tau*, and pericyte-deficient transgenic models

  Mouse line, construct, promoter                                                                                                    Findings                                                                                                                                                                                                                                                               Age                                      Region                                Reference            Brain Aβ                                          CAA           Neurodegenerative and behavior changes                 Reference
  ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------- -------------------- ------------------------------------------------- ------------- ------------------------------------------------------ -----------------------------------------
  **[Tg APP models]{.ul}**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ***APP^Sw/0^* (Tg2576)**, *hAPP695*, *K670M/N671L*, hPrP                                                                           Fibrin perivascular deposits, BBB leakage of Evans blue                                                                                                                                                                                                                6 and 12 mo; not studied before 6 mo     Cortex, hippocampus                   [@bib132]            7--10 mo                                          9--12 mo      6--9 mo                                                [@bib75]; [@bib45]; [@bib97]; [@bib175]
                                                                                                                                     Loss of BBB tight junctions,[^a^](#ttbl1n2){ref-type="table-fn"} LRP1 endothelial expression, PDGFRβ^+^ pericytes, VSMCs                                                                                                                                               18 mo; not studied before 18 mo          Cortex                                [@bib130]                                                                                                                                   
                                                                                                                                     IgG perivascular deposits, loss of CD13^+^ pericytes, endothelial degeneration                                                                                                                                                                                         1, 3, 6, and 9 mo                        Cortex, hippocampus                   [@bib139]                                                                                                                                   
                                                                                                                                     IgG perivascular deposits, albumin perivascular deposits, microhemorrhages,[^b^](#ttbl1n3){ref-type="table-fn"},[^c^](#ttbl1n4){ref-type="table-fn"} endothelial degeneration, pericyte degeneration, VSMC loss, swollen astrocytic end-feet                           17 and 25 mo; not studied before 17 mo   Cortex, hippocampus, thalamus         [@bib97]                                                                                                                                    
                                                                                                                                     BBB leakage of Evans blue, BBB leakage of exogenous tracers                                                                                                                                                                                                            4 and 10 mo                              Cortex                                [@bib165]                                                                                                                                   
                                                                                                                                     Loss of BBB tight junctions[^a^](#ttbl1n2){ref-type="table-fn"},[^d^](#ttbl1n5){ref-type="table-fn"}                                                                                                                                                                   18 and 24 mo; not studied before 18 mo   Cortex, hippocampus                   [@bib20]                                                                                                                                    
                                                                                                                                     Loss of LRP1 endothelial expression                                                                                                                                                                                                                                    4 and 6 mo                               Cortex, hippocampus, thalamus         [@bib39]                                                                                                                                    
                                                                                                                                     Increased RAGE vascular expression                                                                                                                                                                                                                                     9 mo; not studied before 9 mo            Cortex, hippocampus                   [@bib38]                                                                                                                                    
                                                                                                                                     Genetically increased LRP1 expression in brain microvessels                                                                                                                                                                                                            16 and 24 mo; not studied before 16 mo   Cortex                                [@bib13]             Slowed down                                       Slowed down   Not studied                                            [@bib13]
  ***APP^Sw/0^; Pdgfrβ^+/−^***, accelerated loss of pericytes                                                                        IgG perivascular deposits, loss of CD13^+^ pericytes                                                                                                                                                                                                                   1, 3, 6, and 9 mo                        Cortex, hippocampus                   [@bib139]            Accelerated, +tau pathology and loss of neurons   Accelerated   Accelerated                                            [@bib139]
  ***APP^Sw/0^; Slc2a1^+/−^***, *GLUT1* endothelial haploinsufficiency                                                               Fibrin perivascular deposits, IgG perivascular deposits, and loss of BBB tight junctions,[^a^](#ttbl1n2){ref-type="table-fn"},[^d^](#ttbl1n5){ref-type="table-fn"} LRP1 endothelial expression, GLUT1 endothelial expression                                           2 wk and 1, 8--10, 12, and 16 mo         Cortex, hippocampus                   [@bib178]            Accelerated, +loss of neurons                     Not studied   Accelerated                                            [@bib178]
  ***APP^Sw/0^; mdr1a/b^--/--^***, loss of *Pgp* endothelial function                                                                Loss of Pgp endothelial expression, BBB leakage of Pgp substrate, loss of LRP1 endothelial expression                                                                                                                                                                  2 and 3 mo                               Striatum, cortex, hippocampus         [@bib31]             Accelerated                                       Not studied   Not studied                                            [@bib31]
  ***APP^Sw/0^; Picalm^+/−^***, *PICALM* endothelial haploinsufficiency                                                              Loss of PICALM endothelial expression                                                                                                                                                                                                                                  3 mo                                     Cortex, hippocampus                   [@bib187]            Accelerated                                       Accelerated   Accelerated                                            [@bib187]
  ***APP V717F* (PDAPP)**, *hAPP* full-length, *V717F*, *PDGFb*                                                                      Fibrin perivascular deposits, BBB leakage of Evans blue                                                                                                                                                                                                                6 and 12 mo; not studied before 6 mo     Cortex, hippocampus                   [@bib132]            6--9 mo                                           10--12 mo     6 mo                                                   [@bib132]; [@bib175]
  ***PD-hAPP***, *hAPP* minigene, *V717F/K670M/N671L*, PDGFb                                                                         Blockade of RAGE                                                                                                                                                                                                                                                       9 mo                                     Cortex, hippocampus                   [@bib38]             Slowed down                                       Not studied   Not studied                                            [@bib38]
  ***APP^SwI^* (TgCRND8)**, *hAPP695*, *K670M/N671L/V717F*, hPrP                                                                     Fibrin perivascular deposits, BBB leakage of Evans blue                                                                                                                                                                                                                6 and 12 mo; not studied before 6 mo     Cortex, hippocampus                   [@bib132]            3 mo                                              6--7 mo       3 mo                                                   [@bib45]; [@bib175]
                                                                                                                                     Fibrin perivascular deposits                                                                                                                                                                                                                                           6 mo; not studied before 6 mo            Cortex                                [@bib30]                                                                                                                                    
  ***APP^SwDI^***, *hAPP770*, *K670M/N671L/E693Q/D694N*, mThy1                                                                       Albumin perivascular deposits                                                                                                                                                                                                                                          6 mo; not studied before 6 mo            Dorsal subiculum                      [@bib96]             3--6 mo                                           6 mo          3--6 mo                                                [@bib37]; [@bib39]
                                                                                                                                     Loss of LRP1 endothelial expression                                                                                                                                                                                                                                    4 and 6 mo                               Cortex, hippocampus, and thalamus     [@bib39]                                                                                                                                    
                                                                                                                                     Genetically decreased LRP1 expression in brain microvessels                                                                                                                                                                                                            16 and 24 mo; not studied before 16 mo   Cortex                                [@bib13]             Accelerated                                       Accelerated   Not studied                                            [@bib13]
  ***APP^Sw^* (APP23)**, *hAPP751*, *K670M/N671L*, mThy1                                                                             Microhemorrhages,[^b^](#ttbl1n3){ref-type="table-fn"},[^c^](#ttbl1n4){ref-type="table-fn"} leukocyte infiltration                                                                                                                                                      16 and 30 mo; not studied before 16 mo   Cortex, thalamus                      [@bib12]             6 mo                                              12 mo         3 mo                                                   [@bib175]
  ***TetO-APP^SwI^***, *hAPP695*, *K670M/N671L/V717F*, tetracycline-responsive promoter                                              Microhemorrhages,[^b^](#ttbl1n3){ref-type="table-fn"},[^c^](#ttbl1n4){ref-type="table-fn"} increased BBB permeability to iodinated contrast agent                                                                                                                      14 mo; not studied before 14 mo          Cortex, hippocampus, thalamus         [@bib160]            2--6 mo                                           14 mo         Not studied                                            [@bib160]
  ***APP^SwArc^* (ArcAβ)**, *hAPP695*, *K670M/N671L/E693G*, mPrP                                                                     Microhemorrhages[^e^](#ttbl1n6){ref-type="table-fn"} and increased BBB permeability to gadolinium contrast agent                                                                                                                                                       9 and 21 mo; not studied before 9 mo     Cortex, hippocampus, olfactive bulb   [@bib92], [@bib94]   6 mo                                              9--15 mo      6 mo                                                   [@bib93]
  ***APP^Sw/0^; PSEN1^ΔE9^***, *m/hAPP695 K595N/M596L* × *hPSEN1dE9*, mPrP                                                           Microhemorrhages[^b^](#ttbl1n3){ref-type="table-fn"},[^c^](#ttbl1n4){ref-type="table-fn"}                                                                                                                                                                              9 mo; not studied before 9 mo            Cortex                                [@bib89]             6--7 mo                                           6 mo          6 mo                                                   [@bib46]; [@bib175]
                                                                                                                                     Fibrin perivascular deposits                                                                                                                                                                                                                                           10 mo; not studied before 10 mo          Hippocampus, periventricular zone     [@bib109]                                                                                                                                   
  ***APP^Sw/0^; PSEN1^M146L^***, *hAPP695 K670M/N671L* × *PSEN1 M146L*, hPrP                                                         Microhemorrhages,[^b^](#ttbl1n3){ref-type="table-fn"},[^c^](#ttbl1n4){ref-type="table-fn"} albumin perivascular deposits, immunoglobulin extravasation, endothelial degeneration                                                                                       5 and 11 mo                              Cortex, hippocampus, thalamus         [@bib97]             3--6 mo                                           10 mo         3 mo                                                   [@bib97]
  ***APP^SwFlLo^; PSEN1^M146L/L286V^* (5xFAD or Tg6799)**, *hAPP695*, *K670M/N671L/I716V/V717I*, mThy1, *PSEN1 M146L/L286V*, mThy1   IgG perivascular deposits                                                                                                                                                                                                                                              9 and 10 mo; not studied before 9 mo     Cortex                                [@bib129]            2 mo                                              Not studied   4--5 mo                                                [@bib126]; [@bib175]
                                                                                                                                     Loss of LRP1 endothelial expression                                                                                                                                                                                                                                    7 mo; not studied before 7 mo            Cortex                                [@bib156]                                                                                                                                   
                                                                                                                                     Loss of GLUT1 endothelial expression, increased RAGE vascular expression, increased MMP-9 vascular expression, loss of BBB tight junctions[^a^](#ttbl1n2){ref-type="table-fn"},[^d^](#ttbl1n5){ref-type="table-fn"},[^f^](#ttbl1n7){ref-type="table-fn"}               8 mo; not studied before 8 mo            Cortex                                [@bib95]                                                                                                                                    
  **[Tg PSEN1 models]{.ul}**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ***PSEN1^−/−^***                                                                                                                   Microhemorrhages,[^e^](#ttbl1n6){ref-type="table-fn"} endothelial degeneration                                                                                                                                                                                         E18.5                                    Neocortex                             [@bib176]            Not studied                                       Not studied   Not studied (perinatal lethality)                      [@bib176]
  ***PSEN1^M146V^***                                                                                                                 Microhemorrhages,[^e^](#ttbl1n6){ref-type="table-fn"} basement membrane degeneration                                                                                                                                                                                   10 and 37 mo                             Cortex, hippocampus                   [@bib53]             24 mo                                             No CAA        Not studied                                            [@bib29]
  **[Tg tau models]{.ul}**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ***TetO-Tau^P301L^* (rTg4510)**, *hMAPT P301L*, tetracycline-responsive promoter                                                   BBB leakage of Evans blue, IgG perivascular deposits, microhemorrhages,[^e^](#ttbl1n6){ref-type="table-fn"} leukocyte infiltration                                                                                                                                     9 and 12 mo                              Cortex and hippocampus                [@bib21]             No Aβ pathology; Tau pathology 12 mo              None          Not studied                                            [@bib21]
  **[Tg pericyte-deficient models]{.ul}**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ***Pdgfrβ^+/−^***                                                                                                                  Loss of pericytes, IgG perivascular deposits, fibrin perivascular deposits, thrombin and plasmin brain extravasation, loss of BBB tight junctions,[^a^](#ttbl1n2){ref-type="table-fn"},[^d^](#ttbl1n5){ref-type="table-fn"} brain extravasation of exogenous tracers   1, 6, 8, 14, and 16 mo                   Cortex, hippocampus                   [@bib14]             Not studied                                       Not studied   6--9 mo, +neurodegenerative changes, loss of neurons   [@bib14]; [@bib91]
  ***Pdgfrβ^F7/F7^***                                                                                                                Loss of pericytes, IgG perivascular deposits, fibrin perivascular deposits, thrombin and plasmin brain extravasation, loss of BBB tight junctions,[^a^](#ttbl1n2){ref-type="table-fn"},[^d^](#ttbl1n5){ref-type="table-fn"} brain extravasation of exogenous tracers   6 and 8 mo; not studied before 6 mo      Cortex, hippocampus                   [@bib14]             Not studied                                       Not studied   6--9 mo, +neurodegenerative changes, loss of neurons   [@bib14]
                                                                                                                                     Fibrin perivascular deposits                                                                                                                                                                                                                                           1, 2, 3, 4, 8, and 12 mo                 Cortex, hippocampus, striatum         [@bib122]                                                                                                                                   

APP, amyloid precursor protein; CAA, cerebral amyloid angiopathy; GLUT1, glucose transporter 1; hPrP, hamster prion promoter; IgG, immunoglobulin G; LRP1, low-density lipoprotein receptor-related protein 1; MAPT, microtubule-associated protein tau; MMP-9, matrix metalloproteinase-9; mPrP, mouse prion promoter; mThy1, mouse thymus cell antigen 1 promoter; PDGFRβ, platelet-derived growth factor receptor β; Pgp, P-glycoprotein; PICALM, phosphatidylinositol binding clathrin assembly protein; PSEN1, presenilin 1; RAGE, receptor for advanced glycation end products; VSMC, vascular smooth muscle cell.

Loss of BBB tight junctions as shown by high-resolution confocal microscopy analysis.

Microhemorrhages (hemosiderin deposits) at the capillary level.

Microhemorrhages (hemosiderin deposits) at the arteriolar level.

Loss of BBB tight junctions as shown by immunoblotting of isolated brain capillaries.

The exact vascular location is difficult to determine.

Loss of BBB tight junctions as shown by electron microscopy analysis.

Several independent studies have shown BBB breakdown in *APP^Sw/0^* mice harboring the Swedish double *APP* mutation (KM670/671NL) driven by the hamster prion gene promoter ([@bib75]). This mutation increases abnormal cleavage of cellular APP by β-secretase, causing Aβ overproduction. The BBB breakdown has been demonstrated by capillary leakages of blood-derived fibrinogen, IgG, and albumin; BBB leakage of intravenously administrated Evans blue; and immunohistological and electron microscopy studies showing degeneration and loss of brain capillary pericytes, endothelial cells, vascular smooth muscle cells (VSMCs), loss of endothelial tight junction proteins, and cerebral microhemorrhages ([@bib97]; [@bib132]; [@bib20]; [@bib131]; [@bib139]; [Table 1](#tbl1){ref-type="table"}). Previous studies have shown that leakage of molecules across the BBB could be caused by a loss and/or misalignment of the tight junction proteins and/or enhanced bulk flow fluid transcytosis across the BBB ([@bib186]). Additionally, pericyte degeneration has been shown to lead to BBB disruption at the level of brain capillaries ([@bib5]; [@bib14]; [@bib35]). VSMC degeneration is associated with the breakdown of vascular integrity at the level of small arterioles and arteries, often causing microhemorrhages ([@bib73]; [@bib13]). Brain endothelial degeneration is typically seen with advanced damage to the BBB at the capillary level ([@bib191]).

Studies examining the time course between BBB breakdown and other pathologies indicated that BBB breakdown develops early in *APP^Sw/0^* mice (at 1, 3, and 6 mo of age; [@bib165]; [@bib132]; [@bib139]) before Aβ deposition, cerebral amyloid angiopathy (CAA), and/or behavioral deficits that develop later (at 7--10, 9--12, and 6--9 mo of age, respectively; [@bib45]; [@bib175]). The underlying mechanisms of early BBB disruption in *APP^Sw/0^* mice remain elusive but likely involve direct vasculotoxic effects of oligomeric Aβ and/or other APP-mediated toxic effects on vasculature.

The role of BBB breakdown in the development of brain pathologies has been supported by findings showing that loss of pericytes causing an accelerated BBB breakdown also accelerates parenchymal Aβ deposition and CAA and leads to tau pathology and neuronal loss, which is not seen in *APP^Sw/0^* mice but has been shown in double-transgenic *APP^Sw/0^*; *Pdgfrβ^+/−^* (platelet-derived growth factor receptor β) mice with accelerated pericyte loss ([@bib139]).

Aberrant expression of BBB transporters and/or receptors in cerebral microvessels has also been shown in *APP^Sw/0^* mice and other *APP* models. This includes low levels of low-density lipoprotein receptor--related protein 1 (LRP1), a major clearance receptor for Aβ toxin at the BBB ([@bib39]). Its diminished expression in brain capillaries precedes onset of Aβ pathology and behavioral deficits in *APP^Sw/0^* mice and triple-transgenic *APP^SwDI^* mice carrying three human *APP* mutations (Swedish, Dutch, and Iowa) under the control of the mouse Thy1 neuronal promoter ([@bib39]). Genetic approaches have demonstrated that increasing or diminishing LRP1 levels in cerebral blood vessels slows down or accelerates Aβ pathology and CAA in *APP^Sw/0^* and *APP^SwDI^* mice, respectively ([@bib13]; [Table 1](#tbl1){ref-type="table"}). Genetic deletion of LRP1 from brain endothelium also accelerates Aβ pathology in *5xFAD* mice ([@bib156]) carrying three *APP* mutations (Swedish, Florida, and London) and two Presenilin 1 human mutations (*PSEN1 M146L* and *PSEN1 L286V*; [@bib126]) causing ADAD ([@bib87]).

Expression of the receptor for advanced glycation end products (RAGE), a major Aβ influx receptor at the BBB, is increased in brain microvessels in *APP^Sw/0^* and *5xFAD* mice, which accelerates reentry of circulating Aβ into the brain, causing Aβ accumulation, CBF reductions, and a neuroinflammatory response ([@bib38]) and BBB breakdown ([@bib95]), respectively. Blockade of RAGE slows down Aβ pathology and behavioral deficits in PD-h*APP* mice expressing a mutant form of human *APP* encoded by a minigene containing several substitutions from ADAD (V717F, K670M, and N761L) under the control of platelet-derived growth factor B (PDGF-B) chain promoter ([@bib38]; [Table 1](#tbl1){ref-type="table"}).

*APP^Sw/0^* mice develop an early GLUT1 BBB dysfunction that reduces brain glucose uptake ([@bib124]). Moreover, diminished GLUT1 expression in brain endothelium leads to BBB breakdown and transcriptionally inhibits LRP1. This accelerates Aβ pathology and leads to secondary neurodegenerative changes, loss of neurons, and brain atrophy, as shown in double-transgenic *Slc2a1^+/−^*; *APP^Sw/0^* mice with GLUT1 endothelial-specific haploinsufficiency ([@bib178]). Loss of brain endothelial Pgp efflux transporter also diminishes LRP1 expression at the BBB and leads to brain accumulation of Aβ, as shown in triple-transgenic *APP^Sw/0^; mdr1a/b*^−/−^ (Pgp-null) mice ([@bib31]). Additionally, Pgp endothelial dysfunction diminishes active efflux at the BBB, leading to brain accumulation of potentially neurotoxic xenobiotics such as environmental pollutants, food additives, pesticides, and drugs ([@bib113]).

Recent studies have shown that brain endothelial deficiency in the phosphatidylinositol-binding clathrin assembly (PICALM) protein encoded by the *PICALM* gene, a highly validated genetic risk factor for human AD ([@bib67]; [@bib98]; [@bib77]), accelerates Aβ deposition in *APP^Sw/0^* mice, consistent with its critical role in regulating LRP1-mediated Aβ internalization at the abluminal side of the BBB and Aβ transcytosis and clearance across the BBB via Rab5- and Rab11-guided vesicular trafficking ([@bib187]; [Table 1](#tbl1){ref-type="table"}).

Several studies using other *APP* transgenic models, such as *APP* V717F, *APP^Sw/I^* (Swedish, Indiana), *APP^SwDI^*, and *APP^Sw/Arc^* (Swedish, Arctic), and *APP* mice crossed with *PSEN1* ADAD mutants, confirmed BBB breakdown, including fibrinogen, IgG, and albumin perivascular deposits; BBB leakage of Evans blue and contrast imaging agents; microhemorrhages; leukocyte infiltration; loss of tight junctions; and diminished GLUT1 and LRP1 expression at the BBB ([Table 1](#tbl1){ref-type="table"}). Collectively, these data provide strong experimental support for the role of BBB breakdown and dysregulated BBB transport in AD pathophysiology.

BBB breakdown in *PSEN1* transgenic models {#s05}
==========================================

*PSEN1* ADAD mutations lead to elevated Aβ production ([@bib161]; [@bib134]; [@bib87]; [@bib47]), neuronal dysfunction ([@bib100]; [@bib86]), and major cerebrovascular pathology, including BBB breakdown; pericyte degeneration; Aβ capillary, arteriolar, and arterial deposits; and decreased BBB glucose uptake, as shown by human postmortem studies ([@bib43]; [@bib107]; [@bib4]) and imaging studies in the living human brain ([@bib11]; [@bib16]; [@bib51]), respectively. Consistent with these findings, *PSEN1*-knockout mice ([@bib176]) and mice expressing *PSEN1* mutations driven by the neuronal Thy1 promoter ([@bib53]) develop BBB breakdown and microhemorrhages and loss of BBB integrity and reductions in microvasculature, suggesting loss-of-function vascular phenotype in the absence of CAA and/or other Aβ-related pathology. Vascular and BBB changes are also seen in *PSEN1* models crossed with *APP* mice ([@bib97]; [@bib89]; [Table 1](#tbl1){ref-type="table"}).

BBB breakdown in *Tau* transgenic mice {#s06}
======================================

BBB leakage of Evans blue, IgG perivascular deposits, microhemorrhages, and leukocyte infiltration indicating BBB breakdown have been shown in *hTau.P301L* mice before significant accumulation of tau pathology ([@bib21]; [Table 1](#tbl1){ref-type="table"}) and in the absence of CAA and/or other Aβ pathology. These mice carry a Pro to Leu mutation at codon 301 of the tau gene driven by an inducible Tet-on promoter. In humans, this tau mutation leads to early-onset frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) that is characterized by extensive tau pathology ([@bib101]). Whether the underlying mechanisms of BBB breakdown involve disrupted tau clearance across the BBB or direct vasculotoxic effects of tau remains unclear at present. Interestingly, *Tau P301L* mice actually outperform wild-type littermates in behavioral tests within the first 2--3 mo of age ([@bib22]), before the onset of BBB breakdown, raising the possibility that other pathologies, including BBB breakdown, may contribute to dementia and motor symptoms. Because tau pathology is seen in AD, these findings are relevant to AD dementia as well. Future studies should determine the role of BBB breakdown and tau clearance across the BBB in models of dementias caused by tau pathology.

BBB breakdown in *Pdgfrβ-deficient* transgenic mice {#s07}
===================================================

Pericyte-deficient transgenic mice, including *Pdgfrβ^+/−^* mice and *Pdgfrβ^F7/F7^* mice with disrupted *Pdgfrβ* signaling, develop an early and progressive BBB breakdown ([@bib14]; [@bib35]; [@bib122]) and impaired hemodynamic responses ([@bib91]) beginning at 1 mo of age. These vascular changes lead to secondary neurodegeneration, loss of cortical and hippocampal neurons, and behavioral deficits at 6--9 mo of age ([Table 1](#tbl1){ref-type="table"}). Loss of pericytes in mice with diminished PDGF-BB bioavailability also leads to an early BBB breakdown ([@bib5]) and calcium deposition in the basal ganglia detectable at 1 yr of age ([@bib88]; [@bib170]). Because pericytes degenerate in human AD and other neurodegenerative disorders ([@bib159]), these findings support vascular-mediated neurodegeneration independent of Aβ and tau pathology.

BBB breakdown in *APOE* transgenic models {#s08}
=========================================

The apolipoprotein E (*APOE*) gene is the strongest genetic risk factor for AD ([@bib171]; [@bib193]; [@bib102]). One and two *APOE* ε4 alleles increase risk by ∼3.8- and ∼12-fold, respectively, compared with ε3/ε3 genotype, respectively. The effect of one ε4 allele on AD risk is stronger in females than in males. One copy of *APOE* ε2 allele decreases risk by ∼0.6-fold relative to ε3/ε3 genotype. Additionally, *APOE4* increases the risk of CAA.

APOE exerts its toxic effects on the cerebrovascular system ([@bib193]) and neurons ([@bib106]) and influences Aβ clearance, amyloid deposition, and tau-related neurodegeneration in an allele-dependent manner (ε4\>ε3\>ε2; [@bib74]; [@bib102]). Despite the fact that *APOE* has such a strong effect on AD risk, we still lack a comprehensive understanding of how the effects of *APOE* on the cerebrovascular system and other aspects of its function contribute to AD. We also do not have an effective ApoE-based therapy for AD.

*Apoe^−/−^* mice lacking mouse apolipoprotein E (Apoe) develop BBB breakdown, as shown by accumulation of perivascular IgG, fibrinogen, thrombin, and hemosiderin deposits; leakage of Evans blue, different exogenous tracers, or MRI contrast agents; penetration of *N*-methyl-[d]{.smallcaps}-aspartate receptor antibodies; loss of tight junctions; basement membrane degeneration; and loss of perivascular pericytes ([@bib52]; [@bib110]; [@bib117]; [@bib62]; [@bib123]; [@bib15]; [@bib66]; [@bib153]; [@bib27]; [@bib44]; [Table 2](#tbl2){ref-type="table"}). These studies indicate that Apoe is essential for maintaining BBB integrity.

###### BBB breakdown in *APOE* transgenic models

  Mouse line                    Findings                                                                                                                                                                                                                                                                                                                                                                                                                Age                              Region                                                    Reference
  ----------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- --------------------------------------------------------- --------------------
  *Apoe^−/−^*                   BBB leakage of Evans blue, IgG perivascular deposits                                                                                                                                                                                                                                                                                                                                                                    2 and 3 mo                       Hippocampus, cerebellum, spinal cord                      [@bib52]
                                BBB leakage of Evans blue, BBB leakage of peroxidase                                                                                                                                                                                                                                                                                                                                                                    1.5 and 2 mo                     Cortex                                                    [@bib110]
                                IgG perivascular deposits, brain leakage of exogenous tracer (sodium fluorescein)                                                                                                                                                                                                                                                                                                                                       11 mo                            Hippocampus, cerebellum                                   [@bib117]
                                BBB leakage of Evans blue                                                                                                                                                                                                                                                                                                                                                                                               3 and 4 mo                       Cortex, cerebellum                                        [@bib62]
                                BBB leakage of Evans blue                                                                                                                                                                                                                                                                                                                                                                                               6 mo                             Cortex, cerebellum                                        [@bib123]
                                BBB extravasation of exogenous tracers (Dextran and Cadaverine), fibrin perivascular deposits, thrombin perivascular deposits, IgG perivascular deposits, hemosiderin deposits, loss of CD13^+^/PDGFRβ^+^ pericytes, loss of BBB tight junctions,[^a^](#ttbl2n2){ref-type="table-fn"},[^b^](#ttbl2n3){ref-type="table-fn"} increased MMP-9 vascular expression                                                          2 wk and 4, 6, 8, 9, and 18 mo   Cortex, hippocampus                                       [@bib15]
                                Fibrin perivascular deposits, loss of PDGFRβ^+^ pericytes, basement membrane degeneration                                                                                                                                                                                                                                                                                                                               9 mo                             Cortex                                                    [@bib153]
                                BBB leakage of extracted immunoglobulin fractions directed against NMDAR, behavior alterations after injection of immunoglobulin fractions directed against NMDAR                                                                                                                                                                                                                                                       3 and 4 mo                       Cortex, hippocampus, cerebellum, brainstem, spinal cord   [@bib66]; [@bib27]
                                IgG perivascular deposits, increased BBB permeability to Gadolinium contrast agent                                                                                                                                                                                                                                                                                                                                      10 and 11 mo                     Periventricular zone, fornix fimbria (hippocampus)        [@bib44]
  TR-*APOE4* and GFAP-*APOE4*   BBB extravasation of exogenous tracers (Dextran and Cadaverine), fibrin perivascular deposits, thrombin perivascular deposits, IgG perivascular deposits, microhemorrhages (hemosiderin deposits),[^c^](#ttbl2n4){ref-type="table-fn"} loss of CD13^+^/PDGFRβ^+^ pericytes, loss of BBB tight junctions,[^a^](#ttbl2n2){ref-type="table-fn"},[^b^](#ttbl2n3){ref-type="table-fn"} increased MMP-9 vascular expression   2 wk and 4, 6, 8, 9, and 18 mo   Cortex, hippocampus                                       [@bib15]
  TR-*APOE4*                    Basement membrane degeneration, loss of GLUT1 endothelial expression, increased RAGE endothelial expression                                                                                                                                                                                                                                                                                                             12 mo                            Cortex, hippocampus                                       [@bib2]
                                Microhemorrhages (hemosiderin deposits)[^d^](#ttbl2n5){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                             6 and 7 mo                       Cortex                                                    [@bib25]
  *APOE4* knock-in              BBB leakage of Evans blue                                                                                                                                                                                                                                                                                                                                                                                               6 mo                             Cortex, cerebellum                                        [@bib123]

APOE, apolipoprotein E; GFAP, glial fibrillary acidic protein; GLUT1, glucose transporter 1; IgG, immunoglobulin G; MMP-9, matrix metalloproteinase-9; NMDAR, *N*-methyl-[d]{.smallcaps}-aspartate receptor; PDGFRβ, platelet derived growth factor β; RAGE, receptor for advanced glycation end products; TR, targeted replacement.

Loss of BBB tight junctions as shown by high-resolution confocal microscopy analysis.

Loss of BBB tight junctions as shown by immunoblotting of isolated brain capillaries.

Microhemorrhages (hemosiderin deposits) at the capillary level.

Microhemorrhages (hemosiderin deposits) at the capillary and arteriolar level.

Studies using transgenic mice with targeted replacement of mouse Apoe with each human APOE isoform (TR-*APOE*) or mice expressing each human APOE isoform under control of the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter on an Apoe-null background, have shown that expression of APOE4, but not APOE2 and APOE3, leads to BBB breakdown ([@bib123]; [@bib15]) and cerebral microhemorrhages ([@bib25]; [Table 2](#tbl2){ref-type="table"}). Loss of endothelial GLUT1 expression and increased expression of RAGE have also been shown in TR-*APOE4* mice, but not TR-*APOE3* or TR-*APOE2* mice ([@bib2]). Studies in human *APOE4* carriers compared with noncarriers have also demonstrated a more pronounced BBB breakdown and pericyte degeneration ([@bib140]; [@bib190]; [@bib78]; [@bib195]; [@bib65]), diminished regional BBB uptake of glucose ([@bib127]; [@bib135]), and early neurovascular dysfunction ([@bib137]; [@bib147]; [@bib163]; [@bib63]; [@bib157]).

Genetic ablation, siRNA silencing, and pharmacological studies in transgenic *APOE4* mice revealed that activation of the proinflammatory cyclophilin A (CypA)--matrix metalloproteinase 9 (MMP-9) pathway in pericytes leads to degradation of tight junction and basement membrane proteins causing BBB breakdown ([@bib15]). Interestingly, neuropathological findings in AD *APOE4* carriers compared with noncarriers also demonstrate elevated levels of CypA and MMP-9 in brain endothelium and pericytes that correlate with elevated IgG and fibrinogen capillary leakages, suggesting activation of the CypA-MMP-9 BBB degrading pathway ([@bib65]). Cerebrospinal fluid analysis in *APOE4* nonsymptomatic carriers compared with noncarriers confirmed that activation of the CypA--MMP9 pathway correlates with BBB breakdown ([@bib64]), which has been also corroborated by tissue CypA mRNA analysis ([@bib33]).

An early and progressive BBB breakdown detectable in TR-*APOE4* and GFAP-*APOE4* mice between 2 and 6 wk of age precedes changes in sensory-evoked neuronal functioning, loss of neuritic density, and loss of pre- and postsynaptic proteins that develop at 4 mo of age ([@bib15]). Importantly, pharmacologic inhibition of the CypA--MMP-9 BBB pathway in addition to repairing the BBB also slowed down and reversed neurodegenerative changes in *APOE4* and *Apoe^−/−^* mice. Similarly, genetic inhibition of the CypA--MMP-9 pathway at the BBB reversed neurodegenerative changes in *Apoe^−/−^* mice ([@bib15]). Because *Apoe^−/−^* ([@bib136]; [@bib15]; [@bib99]) and *APOE4* transgenic mice ([@bib15]; [@bib141], [@bib142]; [@bib103]) develop behavioral deficits at 4--6 mo of age after BBB breakdown, collectively, these findings suggest that BBB breakdown ([Table 2](#tbl2){ref-type="table"}) not only contributes to neuronal changes in these models but also is an important therapeutic target.

Several studies have established that human APOE isoforms differentially regulate brain Aβ clearance ([@bib26]), as reviewed elsewhere ([@bib171]; [@bib102]). Consistent with these findings, APOE isoforms differentially regulate Aβ clearance across the BBB ([@bib40]; [@bib187]). Studies in animal models have shown that APOE3 and APOE2 mediate Aβ clearance across the BBB via LRP1, whereas APOE4 preferentially binds to very-low-density lipoprotein receptor (VLDR) at the mouse BBB, which clears ligands across the BBB at much slower rate than LRP1, contributing to brain accumulation of Aβ ([@bib40]).

Potential pitfalls in BBB permeability measurements {#s09}
===================================================

High-resolution confocal microscopy analysis and multiphoton microscopy imaging of various endogenous and exogenous tracers, studies using molecular biomarkers of BBB cellular breakdown and/or dysfunction, electron microscopy studies, and MRI studies strongly support BBB breakdown in animal models of AD and *Apoe^−/−^* and *APOE4* transgenic mice ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Some studies, however, did not detect BBB breakdown in *Apoe^−/−^* and *TR-APOE4* mice using exogenous circulating antibodies (e.g., IgG and anti--β-secretase 1 \[BACE1\]) but showed significant brain uptake of the bispecific therapeutic anti--transferrin receptor--BACE1 antibody, which uses the Trf receptor to cross the BBB ([@bib19]). Interestingly, this study also did not detect BBB breakdown in a superoxide dismutase-1 *SOD1^G93A^* model of amyotrophic lateral sclerosis (ALS) using control IgG and anti--BACE1 antibodies ([@bib19]). In contrast, multiple independent studies in *SOD1^G93A^* mice and other *SOD1* ALS mutants reported an early BBB breakdown using different techniques and approaches ([@bib54],[@bib55]; [@bib188], [@bib189]; [@bib120]; [@bib112]; [@bib177]). Here, we briefly discuss potential reasons for discrepancy between different studies and possible factors that could interfere with interpretation of BBB measurements in animal models.

In brief, the use of systemically administered exogenous macromolecules such as nonimmune antibodies to determine BBB permeability requires extensive vascular perfusion of the brain with cold saline at the end of experiment to eliminate antibodies from cerebral blood vessels ([@bib19]). However, this perfusion step can also remove tracers from the brain, particularly nonfixable ones such as exogenous nonimmune IgG, which tends to underestimate brain uptake values. This could be particularly critical in models with focal and/or rather discrete BBB changes, when tracer concentration is determined in brain homogenates or lysates. To overcome this problem, some studies used tissue-fixable tracers, such as Cadaverine-Alexa Fluor 555 ([@bib5]; [@bib15]) or lysine fixable dextrans ([@bib17]), which after crossing the disrupted BBB remain bound to brain tissue and therefore are easily detectable by either histological or biochemical analysis.

Besides technical challenges, BBB breakdown in models of neurodegenerative disorders ([@bib192]) and in humans with these disorders such as AD ([@bib115]; [@bib118]) typically starts focally ([@bib114]) and then spreads throughout several gray and white matter regions ([@bib167],[@bib168], [@bib169]). In contrast, BBB breakdown in models of neuroinflammation, such as experimental allergic encephalitis, is more widespread and robust ([@bib173]; [@bib146]), similar to multiple sclerosis in humans, where BBB breakdown develops more rapidly and is typically an order of magnitude greater than in neurodegenerative disorders such as AD ([@bib115]). Thus, experimental approaches that rely solely on biochemical analysis of the exogenous tracer's concentration in brain lysates without additionally using tissue imaging analysis might run the risk of missing subtle changes in BBB integrity around brain capillaries first affected by the disease process, which are otherwise detectable by high-resolution confocal or multiphoton microscopy analysis ([@bib132]; [@bib14], [@bib15]).

It is not completely unexpected, therefore, that studies using systemically administered radiolabeled tracers (e.g., dextran and albumin) and assaying their concentration in different CNS tissue lysates were able to readily detect BBB permeability increases in models of neuroinflammation, but not in models of neurodegenerative disorders ([@bib19]). Because multiple independent studies by different groups showed BBB breakdown in models of neurodegeneration using imaging techniques ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}), the question persists whether radiotracer methods alone are sensitive enough to detect focal and less pronounced BBB changes. A recent neuroimaging study in individuals with MCI also suggests that even within a single brain region in humans, as for example in the hippocampus, some subregions may have intact BBB, such as CA3, whereas others such as CA1 and dentate gyrus show BBB breakdown ([@bib114]). Combining different methods and approaches is therefore highly recommended to ascertain whether given animal models develop BBB breakdown.

Targeting BBB to control neurodegeneration {#s10}
==========================================

[Fig. 1](#fig1){ref-type="fig"} illustrates various pathways showing how BBB breakdown and dysregulated transport systems contribute to development of neurodegenerative changes, accumulation of Aβ and tau pathology and neuronal loss, based on findings in animal models of AD ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). In addition to influx of various neurotoxic agents, cells, and pathogens into the brain, BBB breakdown leads to the development of enlarged perivascular spaces (unpublished data), and brain ischemic changes. On the other hand, dysfunction in BBB transport systems leads to the development of Aβ and tau pathology and neuronal loss, as for example in *APP* expressing mice challenged by added vascular hits such as pericyte loss ([@bib139]), diminished GLUT1 ([@bib178]) and LRP1 expression ([@bib156]), or increased RAGE expression ([@bib41]) at the BBB. Here, we discuss therapeutic strategies targeting BBB pathways to control neurodegeneration.

![**Contribution of BBB breakdown and dysregulated BBB transport to AD pathophysiology based on findings in animal models, as shown in** [**Tables 1**](#tbl1){ref-type="table"} **and** [**2**](#tbl2){ref-type="table"}**.** BBB breakdown (left) leads to perivascular accumulation of blood-derived neurotoxic products in the brain, such as red blood cell (RBC)--derived hemoglobin (Hb) and free iron (Fe^2+^) generating reactive oxygen species (ROS) and oxidant stress to neurons; potentially toxic plasma proteins such as fibrin(ogen), plasmin(ogen), thrombin, and/or autoantibodies, which could lead to neuronal injury, cell death, and inflammatory response; and albumin contributing to the development of edema, hypoperfusion, and tissue hypoxia. Pericyte detachment, degeneration, and loss leads to BBB breakdown. Apolipoprotein E (APOE) isoforms differentially regulate pericyte metabolism and BBB integrity. APOE2 and APOE3, but not APOE4, act via low-density lipoprotein receptor--related protein-1 (LRP1) on pericytes to inhibit the proinflammatory cyclophilin A (CypA)--matrix metallopeptidase-9 (MMP-9) pathway. When activated by APOE4, this pathway leads to MMP-9--mediated degradation of BBB tight junction and basement membrane proteins causing BBB breakdown. Dysregulated BBB transport (right) leads to a loss of equilibrium between Alzheimer's amyloid β (Aβ) efflux and influx across the BBB, which is a key mechanism that maintains brain Aβ homeostasis. Aβ efflux is normally mediated via its receptors on brain endothelium, including LRP1, which works closely with phosphatidylinositol-binding clathrin assembly protein (PICALM) to clear Aβ monomers, oligomers, and aggregates from brain across the BBB; LRP2, which clears Aβ in a form of complexes with APOJ (clusterin); and P-glycoprotein (Pgp), which mediates active efflux of Aβ from brain endothelium to blood. LRP1 and Pgp BBB levels are reduced in AD models before Aβ deposition, which contributes to Aβ accumulation in the brain. Aβ influx from blood to brain is mediated by the receptor for advanced glycation end products (RAGE), which also triggers an inflammatory response. RAGE expression at the BBB is increased in AD models, which contributes to Aβ accumulation in the brain and inflammatory response. *APOE* isoforms differentially regulate Aβ clearance. Aβ complexes with human APOE2 and APOE3 isoforms are cleared across the BBB by LRP1. APOE4 has lower affinity for LRP1 and binds to the very-low-density lipoprotein receptor (VLDLR), which slowly transports its ligands across the BBB, including the APOE4--Aβ complex, causing its accumulation in the brain. BBB *GLUT1* transporter delivers glucose to the brain across the BBB and is down-regulated in AD models. Its reduction accelerates BBB breakdown and Aβ pathology and leads to tau pathology and neuronal loss. BBB *MFSD2a* (major facilitator superfamily domain--containing protein 2) transports essential ω-3 fatty acids into the brain, which is essential for brain development, cognition, and maintenance of BBB integrity. Aβ can also accumulate in the perivascular space (PVS) between astrocyte end-feet and the vessel wall because of inefficient drainage along the perivascular route.](JEM_20171406_Fig1){#fig1}

Repairing the BBB with activated protein C (APC) and/or its cell-protective analogues ([@bib59]) not only protects BBB integrity but also slows down the course of a neurological disorder, as shown in the *SOD1^G93A^* ALS model ([@bib177]). APC enhances the integrity of endothelial membranes by activating Rac1-dependent stabilization of the cytoskeleton and/or down-regulating MMP-9 at the BBB, thus protecting the neuroglial environment from systemic influences ([@bib194]). Whether APC can exert similar beneficial effects in AD models with disrupted BBB ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}) remains to be seen. Because 3K3A-APC analogue has completed a phase 2 clinical trial for stroke (NCT02222714), this approach holds promise to translate to patients with other neurological disorders, including AD. It also remains to be determined whether inhibition of the CypA--MMP-9 pathway at the BBB with CypA inhibitors can seal the BBB and exert beneficial effects on cognitive function in human *APOE4* carriers, as it does in transgenic *APOE4* mice ([@bib15]; [Fig. 1](#fig1){ref-type="fig"}). Again, this approach is attractive, because CypA inhibitors are currently being tested in a phase 3 trial for hepatitis C (NCT01318694).

Besides sealing the BBB, eliminating the consequences of BBB breakdown has been investigated. When the BBB is open, plasma proteins enter the neuroglial space and become neurotoxic; therefore, neutralizing toxic accumulates represents a valuable therapeutic approach for neurodegenerative diseases such as AD that are associated with BBB pathology. In fact, depleting accumulated fibrinogen from the brain with ancrod, a defibrinogenating agent, or by genetic manipulation attenuated both neuroinflammation and vascular pathology in *APP* mice ([@bib132]) and in a model of multiple sclerosis ([@bib36]). On the other hand, BBB damage causing RBC extravasation and brain accumulation of free neurotoxic iron causing oxidant stress can be successfully controlled by iron chelators and/or antioxidant treatment, as shown in *SOD1^G93A^* ALS model ([@bib177]; [Fig. 1](#fig1){ref-type="fig"}).

Other approaches, such as using RAGE blockers to inhibit Aβ influx across the BBB and the neurovascular inflammatory response ([@bib38], [@bib41]), have advanced from animal models to a phase 3 trial in AD (NCT02916056). Targeting BBB clearance in AD is an emerging therapeutic approach to restore the balance between Aβ production and clearance. LRP1 minigene delivery to the BBB by viral vectors facilitates Aβ clearance and mitigates Aβ pathology ([@bib178]). The PICALM-dependent transcytotic machinery at the BBB can also be targeted therapeutically by gene therapy ([@bib186]). Additionally, current Aβ clearance treatments with anti--Aβ antibodies to remove Aβ from brain would benefit from intact Aβ transvascular transport and clearance across the BBB, particularly for the antibodies acting mainly through peripheral Aβ sink action (NCT02008357). Therefore, repairing BBB and Aβ BBB clearance mechanisms is critical for success of these treatments as well.

The vascular drainage pathway along the perivascular spaces of CNS vessels contributes to the clearance of molecules from brain extracellular spaces (ECSs), including Aβ ([@bib162]; [@bib9]), and is connected with the cerebrospinal fluid (CSF) compartment and lymphatic vessels within the dura matter of the brain, which drain to the peripheral lymph nodes ([@bib104]; [@bib48]). Additionally, it has been proposed that convective, "glymphatic" flow of CSF through the ECSs from the para-arterial to the paravenous spaces plays a role in solute transport exchanges in parenchymal ECSs ([@bib81]; [@bib84]). However, recent studies have not supported the proposed glymphatic mechanism of convective solute transport in brain parenchyma ([@bib71]; [@bib155]; [@bib149]) or the convective, pressure-driven fluid flow from para-arterial to paravenous spaces through parenchymal ECSs ([@bib8], [@bib7]; [@bib85]; [@bib72]; [@bib149]). The current view states that metabolic waste products and endogenous molecules generated by the brain diffuse away through brain ECSs and are eliminated from the brain by transvascular transport across the BBB ([@bib192]; [@bib186]) and perivascular transport along the vessel walls in the direction opposite the blood flow ([@bib162]; [@bib9]), as originally proposed by physiologists decades ago ([@bib111]; [@bib23]). This clearance pathway extends to toxic metabolites such as Aβ, which in normal mice contributes to ∼15--20% of Aβ clearance from the brain ([@bib148]; [@bib180]); the remaining 80--85% is removed from the brain by transvascular transport across the BBB into the blood. Whether ECSs and perivascular clearance of Aβ can be targeted therapeutically in AD and AD models to remove excess Aβ remains to be explored in future studies.

Future directions {#s11}
=================

Multiple studies have shown BBB breakdown and dysregulated BBB transport in AD models, establishing their roles in neurodegeneration and development of Alzheimer's Aβ and tau pathology. BBB breakdown and dysfunction have also been reported in rare inherited monogenic human neurological disorders with genetic defects affecting exclusively BBB cells, which directly supports the link between BBB breakdown and neurological disorders ([@bib186]). For example, loss-of-function mutations in the human *GLUT1* gene encoding the BBB glucose transporter result in GLUT1-deficiency syndrome with early-onset seizures and microcephaly ([@bib172]). *Glut1^+/−^* mice not only phenocopy human pathology but also develop BBB breakdown, causing microcephaly and neurodegeneration ([@bib178]). The role of diminished GLUT1 expression at the BBB in human AD ([@bib118]) and animal models is still not fully understood; in particular, it is unclear whether pharmacologically reversing GLUT1 expression repairs BBB integrity and reverses neurodegenerative changes, cognitive decline, and behavioral deficits, as suggested by gene therapy studies in *Slc2a1^+/−^*; *APP^Sw/0^* mice with endothelial-specific GLUT1 haploinsufficiency ([@bib178]).

Loss of tight junction proteins causing BBB breakdown has been found both in human AD and animal models. However, their role in disease process remains elusive. In contrast, mutations in the *OCLN* (occludin) gene encoding the tight junction protein occludin ([@bib125]) or the junctional adhesion molecule-C (*JAM-C*) gene encoding junctional molecule JAM-C ([@bib179]; [@bib1]) are causatively related to BBB breakdown, which leads to early-onset seizures, microcephaly, and band-like calcification with simplified gyration in case of *OCLN* mutations or hemorrhages and hydrocephalus, as shown in JAM-C--deficient mice, and/or hemorrhagic destruction of the brain, subependymal, calcification, and congenital cataracts in humans with homozygous mutations of *JAM-C*. Is there any relationship between these findings and findings in complex neurodegenerative disorders such as AD?

Inactivating mutations in major facilitator superfamily domain--containing protein 2a (*MFSD2a*) gene encoding the BBB transporter for essential ω-3 fatty acids cause a lethal microcephaly syndrome ([@bib60]). *Mfsd2a*-deficient mice exhibit impaired brain uptake of ω-3 fatty acids ([@bib18]; [@bib119]), as well as dysregulated caveolae-mediated transcellular trafficking across the BBB and develop BBB breakdown ([@bib17]; [@bib185]; [@bib3]) resulting in microcephaly, neuronal loss, and cognitive deficits. Essential ω-3 fatty acids found in fish oil help reduce the risk of cardiovascular disease and have beneficial effects on cognition. However, the role of the MFSD2a BBB transporter as a possible therapeutic target in AD models and human AD remains underexplored.

Loss-of-function mutations in the *PDGFRB* gene in pericytes lead to idiopathic primary familial brain calcification and motor and cognitive impairment ([@bib88]; [@bib121]). Similarly, *Pdgfb^ret/ret^* mice with severe pericyte loss and BBB breakdown develop deep brain calcification ([@bib88]), whereas *Pdgfrβ^+/−^* and *Pdgfrβ^F7/F7^* pericyte-deficient mice develop BBB breakdown, leading to secondary neurodegeneration ([@bib14]). Pericytes degenerate in AD ([@bib50]; [@bib10]; [@bib143]; [@bib65]) and AD models ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}), but at present, we know very little about whether cell therapies directed at replacing pericytes will have the same beneficial effects in AD models or AD as shown in other models, such as *SOD1^G93A^* ALS ([@bib32]).

Another example is CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). This is an inherited autosomal-dominant ischemic stroke syndrome that progresses to dementia, and it is caused by mutations in the *NOTCH3* gene, which is expressed only in vascular smooth muscle cells and pericytes ([@bib28]). Mice carrying the CADASIL Notch3-R169C mutation also show accumulation of NOTCH ectodomain in pericytes, pericyte degeneration, and BBB breakdown ([@bib57]). Small-vessel disease, on the other hand, is prominent in AD ([@bib79], [@bib80]; [@bib174]) and contributes to ∼50% of all dementias worldwide, including AD ([@bib174]; [@bib116]; [@bib150]; [@bib61]). Thus, it would be interesting to study whether there is a common vascular mechanism predisposing for the development of small ischemic strokes and Alzheimer's pathology in animal models of small-vessel disease.

Finally, as the RNA-sequencing and proteomic studies in animal models have begun to provide new insights into the molecular composition of the BBB and the associated cell types ([@bib105]; [@bib35]; [@bib183]; [@bib68]), our understanding of the cellular and molecular mechanisms of the BBB transport functions will continue to expand. Hopefully, future large-scale single-cell transcriptomic studies of brain endothelial cells, brain capillary pericytes, and smooth muscle cells on arterioles, arteries, and venules will characterize more precisely cell-specific regional expression and zonation of key endothelial transporters on brain capillary, arteriolar, and venular endothelium and determine to which extent the associated mural cells, including pericytes, contribute to the overall transport of solutes exchanges across the BBB.
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